ArticleHuman vaccines & immunotherapeutics2023
Implementing interventions to start HPV vaccination at age 9: Using the evidence we have.
Article in Human vaccines & immunotherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Role of mesenchymal stem cells and their derived exosomes in cervical cancer: Bidirectional mechanisms and research progress (Review).Oncology letters · 2026Review
- Article
- Review
- Parent, Child, and Provider Perspectives on HPV Vaccination in 4-8-Year-Olds: A Mixed Methods Study.Journal of cancer education : the official journal of the American Association for Cancer Education · 2025Article
- Using immunization registry data to explore initiation of HPV vaccination at ages 9 and 10.Human vaccines & immunotherapeutics · 2025Article
- Test Smart, Treat Smart-using clinician feedback to adapt a catheter-associated urinary tract infection intervention for spinal cord injury.PM & R : the journal of injury, function, and rehabilitation · 2025Article
- HPV-Independent Cervical Cancer-A New Challenge of Modern Oncology.International journal of molecular sciences · 2025Review
- Socioeconomic disparities in HPV vaccine uptake: multivariable analysis of vaccination data from Tianjin (2018-2023).Frontiers in public health · 2025Article
- HPV Vaccination Information Access, Needs, and Preferences Among Black and Hispanic Mothers.Journal of health communication · 2024Article
- Update on Oral and Oropharyngeal Cancers: A guide for oral health care providers.Journal of dental hygiene : JDH · 2024Article
- Understanding Barriers to Human Papillomavirus Vaccination among Parents of 9-10-Year-Old Adolescents: A Qualitative Analysis.Vaccines · 2024Article
- Human papillomavirus vaccination at the first opportunity: An overview.Human vaccines & immunotherapeutics · 2023Review
- Age nine is possible: Improving age 9 HPV initiation through a national quality improvement initiative during the COVID-19 pandemic.Human vaccines & immunotherapeutics · 2023Article
- Mothers' perceptions and attitudes about HPV vaccination initiation among 9- and 10-year-olds.Human vaccines & immunotherapeutics · 2023Article
- Evidence supporting the initiation of HPV vaccination starting at age 9: Collection overview.Human vaccines & immunotherapeutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Human papillomavirus (HPV) vaccination is routinely recommended for adolescents aged 11 or 12 years but can begin at age 9. On-time HPV vaccination by the thirteenth birthday has proven to be effective in preventing HPV cancer and pre-cancer. However, HPV coverage rates continue to lag behind other routinely recommended vaccinations for adolescents. A promising approach to improving coverage is to start HPV vaccination at age 9. This approach has been endorsed by the American Academy of Pediatrics and the American Cancer Society. Benefits of this approach include increased time to complete vaccination series by the thirteenth birthday, additional spacing of recommended vaccines, and a more concentrated focus on cancer prevention messaging. While promising, little is known about how and if existing evidence-based interventions and approaches can be used to promote starting HPV vaccination at age 9. Implementation science frameworks offer scientific direction in how to adapt current and develop new interventions to promote starting HPV vaccination at age 9 and accelerate dissemination and prevent HPV cancers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.